CoChat

BIN1 favors the spreading of Tau via extracellular vesicles

Open access

The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.

Abstract

Despite Bridging INtegrator 1 ( BIN1 ) being the second most statistically-significant locus associated to Late Onset Alzheimer’s Disease, its role in disease pathogenesis remains to be clarified. As reports suggest a link between BIN1, Tau and extracellular vesicles, we investigated whether BIN1 could affect Tau spreading via exosomes secretion. We observed that BIN1-associated Tau-containing extracellular vesicles purified from cerebrospinal fluid of AD-affected individuals are seeding-competent. We showed that BIN1 over-expression promotes the release of Tau via extracellular vesicles in vitro as well as exacerbation of Tau pathology in vivo in PS19 mice. Genetic deletion of Bin1 from microglia resulted in reduction of Tau secretion via extracellular vesicles in vitro , and in decrease of Tau spreading in vivo in male, but not female, mice, in the context of PS19 background. Interestingly, ablation of Bin1 in microglia of male mice resulted in significant reduction in the expression of heat-shock proteins, previously implicated in Tau proteostasis. These observations suggest that BIN1 could contribute to the progression of AD-related Tau pathology by altering Tau clearance and promoting release of Tau-enriched extracellular vesicles by microglia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-019-45676-0

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 BIN1 and Tau are present in the EVs purified from CSF. (A,B) Western blotting of post-mortem CSFs samples (reference codes reported) obtained from individuals with neuropathological evaluation of Braak’s stages: 0: Non-Demeted Control, Braak’s Stage III Non-Demented (ND), Braak’s Stage III Demented, Braak’s Stage IV Alzheimer’s Disease, Braak’s Stage IV Alzheimer’s Disease with amyloid deposit C. (A) Western blotting of concentrated CSFs samples showed the presence of various isoforms of BIN1. As control, protein lysates from 293T cells transfected with plasmids expressing BIN1 isoform 6 or isoform 9 were loaded on the gel and indicated by arrows. True-Blot secondary antibodies (Rockland) had been used to avoid detection of non-specific bands. WB image shown represents cropped section of full blot shown in Supplementary Fig. 10. (B) Western blotting of EVs purified by SEC from CSF samples showed the presence of various isoforms of BIN1, pTau181 (short and long exposure indicated by arrows) and TSG101. As controls, EVs purified from Plasma of Healthy Donors and protein lysate from 293T cells co-transfected with plasmids expressing BIN1 isoform 1, 6, 9 and BIN1-13 were loaded on the gel, and indicated by arrows. Plasma EVs show the presence of BIN1, as previously reported34, as well as TSG101. True-Blot secondary antibodies (Rockland) had been used to avoid detection of non-specific bands. WB images shown represent cropped sections of full blots shown in Supplementary Fig. 10. (C) BIN1 and control IgG Immuno-EM was performed on EVs purified by SEC from pooled post-mortem CSF samples from individuals at Braak’s Stages III and IV. Magnification of one representative image out of 5 per sample. Scale: 100 nm. (D) Quantification of the percentage of BIN1+ and IgG+ EVs detected in fraction E1 + E2. Plot represents the mean and SD of three independent experiments performed. Paired parametric two-tailed Student’s t-test (95% confidence): p-value: *p < 0.05; **<0.01; ***p < 0.001.
Figure 1 BIN1 and Tau are present in the EVs purified from CSF. (A,B) Western blotting of post-mortem CSFs samples (reference codes reported) obtained from individuals with neuropathological evaluation of Braak’s stages: 0: Non-Demeted Control, Braak’s Stage III Non-Demented (ND), Braak’s Stage III Demented, Braak’s Stage IV Alzheimer’s Disease, Braak’s Stage IV Alzheimer’s Disease with amyloid deposit C. (A) Western blotting of concentrated CSFs samples showed the presence of various isoforms of BIN1. As control, protein lysates from 293T cells transfected with plasmids expressing BIN1 isoform 6 or isoform 9 were loaded on the gel and indicated by arrows. True-Blot secondary antibodies (Rockland) had been used to avoid detection of non-specific bands. WB image shown represents cropped section of full blot shown in Supplementary Fig. 10. (B) Western blotting of EVs purified by SEC from CSF samples showed the presence of various isoforms of BIN1, pTau181 (short and long exposure indicated by arrows) and TSG101. As controls, EVs purified from Plasma of Healthy Donors and protein lysate from 293T cells co-transfected with plasmids expressing BIN1 isoform 1, 6, 9 and BIN1-13 were loaded on the gel, and indicated by arrows. Plasma EVs show the presence of BIN1, as previously reported34, as well as TSG101. True-Blot secondary antibodies (Rockland) had been used to avoid detection of non-specific bands. WB images shown represent cropped sections of full blots shown in Supplementary Fig. 10. (C) BIN1 and control IgG Immuno-EM was performed on EVs purified by SEC from pooled post-mortem CSF samples from individuals at Braak’s Stages III and IV. Magnification of one representative image out of 5 per sample. Scale: 100 nm. (D) Quantification of the percentage of BIN1+ and IgG+ EVs detected in fraction E1 + E2. Plot represents the mean and SD of three independent experiments performed. Paired parametric two-tailed Student’s t-test (95% confidence): p-value: *p < 0.05; **<0.01; ***p < 0.001.CC BY · PubMed Central
Figure 2 BIN1-associated, Tau-containing EVs are seeding-competent. (A) BIN1 immunoprecipitated EVs show the presence of various isoforms of Tau (long exposure shown) as well as BIN1 with molecular weights compatible with that of isoform 6 and 9 (as shown in lane containing protein lysate from 293T cells transfected with BIN1 isoform 6 and 9 expressing plasmids and indicated by arrows). TST101 represents exosome marker. True-Blot secondary antibodies (Rockland) had been used to avoid detection of non-specific bands. One representative experiment shown out of 3 independent replicates. WB images shown represent cropped sections of full blots shown in Supplementary Fig. 11. (B) Tau immunoprecipitated material shows the presence of various truncated and full-length Tau isoforms (long exposure shown) with molecular weights compatible with control aggregated Tau fibrils (short exposure shown). No BIN1 or TST101 was detected. True-Blot secondary antibodies (Rockland) had been used to avoid detection of non-specific bands. One representative experiment shown out of 3 independent replicates. WB images shown represent cropped sections of full blots shown in Supplementary Fig. 11. (C) Nanoparticle tracking analysis of extracellular vesicles purified by affinity immunopurification with anti-BIN1 from human CSF. One representative experiment out of 3 independent replicates. (D) BIN1 immunoprecipitated EVs (black bars) as well as BIN1 immunodepleted CSFs (gray bars) were prepared from samples obtained from 10 different individuals and tested in the Tau-FRET assay for Tau oligomerization. Results are plotted as Integrated FRET Density values for each sample (reference codes reported). Samples containing pTau and/or oligoTau by previous western blot analysis are highlighted in red. Samples devoid of pTau and/or oligoTau by previous western blot analysis are highlighted in blue. Elution Buffer (EB) serves as a negative control, whereas Tau fibrils (3 μM) serve as a positive control.
Figure 2 BIN1-associated, Tau-containing EVs are seeding-competent. (A) BIN1 immunoprecipitated EVs show the presence of various isoforms of Tau (long exposure shown) as well as BIN1 with molecular weights compatible with that of isoform 6 and 9 (as shown in lane containing protein lysate from 293T cells transfected with BIN1 isoform 6 and 9 expressing plasmids and indicated by arrows). TST101 represents exosome marker. True-Blot secondary antibodies (Rockland) had been used to avoid detection of non-specific bands. One representative experiment shown out of 3 independent replicates. WB images shown represent cropped sections of full blots shown in Supplementary Fig. 11. (B) Tau immunoprecipitated material shows the presence of various truncated and full-length Tau isoforms (long exposure shown) with molecular weights compatible with control aggregated Tau fibrils (short exposure shown). No BIN1 or TST101 was detected. True-Blot secondary antibodies (Rockland) had been used to avoid detection of non-specific bands. One representative experiment shown out of 3 independent replicates. WB images shown represent cropped sections of full blots shown in Supplementary Fig. 11. (C) Nanoparticle tracking analysis of extracellular vesicles purified by affinity immunopurification with anti-BIN1 from human CSF. One representative experiment out of 3 independent replicates. (D) BIN1 immunoprecipitated EVs (black bars) as well as BIN1 immunodepleted CSFs (gray bars) were prepared from samples obtained from 10 different individuals and tested in the Tau-FRET assay for Tau oligomerization. Results are plotted as Integrated FRET Density values for each sample (reference codes reported). Samples containing pTau and/or oligoTau by previous western blot analysis are highlighted in red. Samples devoid of pTau and/or oligoTau by previous western blot analysis are highlighted in blue. Elution Buffer (EB) serves as a negative control, whereas Tau fibrils (3 μM) serve as a positive control.CC BY · PubMed Central
Figure 3 Human BIN1 isoform 9 favors the release of Tau via EVs in vitro as well as increasing the area of pTau staining in vivo. (A) Western blot of Tau and BIN1 in cell lysates (left panel) and EVs (right panel) from HEK293T cells transfected with Tau 2N4R alone or in presence of BIN1 isoform 1 or 9 (indicated by arrows). GAPDH (left panel) represents a cell lysate loading control. CLATHRIN (right panel) serves as an extracellular vesicle loading control. One representative experiment shown out of 4 independent replicates. WB images shown represent cropped sections of full blots shown in Supplementary Fig. 12. (B) Western blot of Tau and BIN1 in cell lysates (left panel) and EVs (right panel) from HEK293T cells transfected with Tau 2N4R P301L-YFP alone or in presence of BIN1 isoform 1 or 9 (indicated by arrows). GAPDH (left panel): cell lysate loading control. CLATHRIN (right panel): extracellular vesicle loading control. One representative experiment shown out of 4 independent replicates. WB images shown represent cropped sections of full blots shown in Supplementary Fig. 12. (C) Experimental scheme. Artwork by Channa Bao. (D) Representative image of Immunohistochemical staining of pTau (40E8) in hippocampi of PS19 mice injected with AAV expressing GFP or GFP-P2A-hBIN1 isoform 9. Scale: 600 μm. (E) Plot representing the percentage of pTau staining area in the ipsilateral hippocampus (area of pTau staining normalized to the size of the ipsilateral hippocampus for each animal). Each triangle represents one animal. Unpaired parametric Student’s t-test two tailed, 95% confidence: p-value: *p < 0.05; **<0.01; ***p < 0.001.
Figure 3 Human BIN1 isoform 9 favors the release of Tau via EVs in vitro as well as increasing the area of pTau staining in vivo. (A) Western blot of Tau and BIN1 in cell lysates (left panel) and EVs (right panel) from HEK293T cells transfected with Tau 2N4R alone or in presence of BIN1 isoform 1 or 9 (indicated by arrows). GAPDH (left panel) represents a cell lysate loading control. CLATHRIN (right panel) serves as an extracellular vesicle loading control. One representative experiment shown out of 4 independent replicates. WB images shown represent cropped sections of full blots shown in Supplementary Fig. 12. (B) Western blot of Tau and BIN1 in cell lysates (left panel) and EVs (right panel) from HEK293T cells transfected with Tau 2N4R P301L-YFP alone or in presence of BIN1 isoform 1 or 9 (indicated by arrows). GAPDH (left panel): cell lysate loading control. CLATHRIN (right panel): extracellular vesicle loading control. One representative experiment shown out of 4 independent replicates. WB images shown represent cropped sections of full blots shown in Supplementary Fig. 12. (C) Experimental scheme. Artwork by Channa Bao. (D) Representative image of Immunohistochemical staining of pTau (40E8) in hippocampi of PS19 mice injected with AAV expressing GFP or GFP-P2A-hBIN1 isoform 9. Scale: 600 μm. (E) Plot representing the percentage of pTau staining area in the ipsilateral hippocampus (area of pTau staining normalized to the size of the ipsilateral hippocampus for each animal). Each triangle represents one animal. Unpaired parametric Student’s t-test two tailed, 95% confidence: p-value: *p < 0.05; **<0.01; ***p < 0.001.CC BY · PubMed Central
Figure 4 Identification and quantification of BIN1 isoform expression in human and mice. (A) Plot representing human BIN1 isoforms transcript expression in total brain lysate (striped bars), in microglia (black bars) and in monocytes (gray bars). Isoform 1 indicated in green; isoform 6 indicated in blue; isoform 9 indicated in red. Data are expressed in Log2 Transcript per million +1 (Log2 (TPM + 1)). (B) Plot representing murine Bin1 isoform 1 (black bars) and isoform 2 (gray bars) transcript expression in various CNS cell types. Data are expressed in Fragments Per Kilobase Million (FPKM).
Figure 4 Identification and quantification of BIN1 isoform expression in human and mice. (A) Plot representing human BIN1 isoforms transcript expression in total brain lysate (striped bars), in microglia (black bars) and in monocytes (gray bars). Isoform 1 indicated in green; isoform 6 indicated in blue; isoform 9 indicated in red. Data are expressed in Log2 Transcript per million +1 (Log2 (TPM + 1)). (B) Plot representing murine Bin1 isoform 1 (black bars) and isoform 2 (gray bars) transcript expression in various CNS cell types. Data are expressed in Fragments Per Kilobase Million (FPKM).CC BY · PubMed Central
Figure 5 Deletion of Bin1 in microglia reduces the release of Tau via EVs in vitro as well as decreases pTau spreading in male mice in vivo. (A) Experimental timeline for in vitro microglia-derived Tau-containing EVs analysis. (B) Western blot of Tau and BIN1 in cell lysates (top) and EVs (bottom) from Bin1 wt and cKO primary microglia cells after administration of Tau fibrils and stimulation with LPS and ATP, as reported in A. β-actin: cell lysate loading control. Exosome marker Alix: EVs loading control. Each experiment performed by pooling together microglia from more than 10 pups of the same genotype. One representative experiment shown out of 4 independent replicates. WB images shown represent cropped sections of full blots shown in Supplementary Fig. 13. (C) Plot representing densitometric analysis of Tau band intensity normalized to Alix band intensity, as obtained by WB from EVs purified from CMs of microglia Bin1 wt and cKO, respectively. Plot represents mean and SD of 4 independent replicates. Paired parametric Student’s t-test two tailed, 95% confidence: p-value: *p < 0.05; **<0.01; ***p < 0.001. (D) Experimental scheme. Artwork by Channa Bao. (E) Representative images of immunohistochemical staining of pTau (40E8) in contralateral hippocampi of Bin1flox/flox:: Cx3Cr1-Cre+::PS19Hemi and Bin1wt:: Cx3Cr1-Cre−::PS19Hemi littermate male mice injected with Tau fibrils. Scale: 700 μm. (F) Plot representing the percentage of pTau staining area normalized to the size of the hippocampus for each animal. Each symbol represents one animal. (G) Representative images of immunohistochemical staining of pTau (40E8) in contralateral hippocampi of Bin1flox/flox:: Cx3Cr1-Cre+:: PS19Hemi and Bin1wt:: Cx3Cr1-Cre−:: PS19Hemi littermate female mice injected with Tau fibrils. Scale: 700 μm. (H) Plot representing the percentage of pTau staining area normalized to over the size of the hippocampus for each animal. Each symbol represents one single animal. Two-way ANOVA with Holm’s p-value adjustment (two-sided) (see Supplementary Fig. 9): p-value: *p < 0.05; **<0.01; ***p < 0.001.
Figure 5 Deletion of Bin1 in microglia reduces the release of Tau via EVs in vitro as well as decreases pTau spreading in male mice in vivo. (A) Experimental timeline for in vitro microglia-derived Tau-containing EVs analysis. (B) Western blot of Tau and BIN1 in cell lysates (top) and EVs (bottom) from Bin1 wt and cKO primary microglia cells after administration of Tau fibrils and stimulation with LPS and ATP, as reported in A. β-actin: cell lysate loading control. Exosome marker Alix: EVs loading control. Each experiment performed by pooling together microglia from more than 10 pups of the same genotype. One representative experiment shown out of 4 independent replicates. WB images shown represent cropped sections of full blots shown in Supplementary Fig. 13. (C) Plot representing densitometric analysis of Tau band intensity normalized to Alix band intensity, as obtained by WB from EVs purified from CMs of microglia Bin1 wt and cKO, respectively. Plot represents mean and SD of 4 independent replicates. Paired parametric Student’s t-test two tailed, 95% confidence: p-value: *p < 0.05; **<0.01; ***p < 0.001. (D) Experimental scheme. Artwork by Channa Bao. (E) Representative images of immunohistochemical staining of pTau (40E8) in contralateral hippocampi of Bin1flox/flox:: Cx3Cr1-Cre+::PS19Hemi and Bin1wt:: Cx3Cr1-Cre−::PS19Hemi littermate male mice injected with Tau fibrils. Scale: 700 μm. (F) Plot representing the percentage of pTau staining area normalized to the size of the hippocampus for each animal. Each symbol represents one animal. (G) Representative images of immunohistochemical staining of pTau (40E8) in contralateral hippocampi of Bin1flox/flox:: Cx3Cr1-Cre+:: PS19Hemi and Bin1wt:: Cx3Cr1-Cre−:: PS19Hemi littermate female mice injected with Tau fibrils. Scale: 700 μm. (H) Plot representing the percentage of pTau staining area normalized to over the size of the hippocampus for each animal. Each symbol represents one single animal. Two-way ANOVA with Holm’s p-value adjustment (two-sided) (see Supplementary Fig. 9): p-value: *p < 0.05; **<0.01; ***p < 0.001.CC BY · PubMed Central
Figure 6 Deletion of Bin1 in microglia affects gene expression in a sexually dimorphic fashion. (A) Heatmap representing FPKM values of 268 differentially expressed genes in microglia from Bin1flox/flox::Cx3Cr1-Cre+, Bin1wt/flox::Cx3Cr1-Cre+ and Bin1wt/flox::Cx3Cr1-Cre− male and female mice (Average Normalized Counts > 4; Fold Change |FC| 1.5; padj < 0.05). (B) Venn diagram representing the distribution of 268 differentially expressed genes across genotypes and sexes. (C) Selection of the most statistically significant Canonical Pathways obtained by Ingenuity Pathway Analysis of the DEGs comparison of Bin1flox/flox::Cx3Cr1-Cre+(Homo KO) versus Bin1wt/flox::Cx3Cr1-Cre− (WT) microglia from male mice (named Homo) and the DEGs comparison of Bin1wt/flox::Cx3Cr1-Cre+(Het KO) versus Bin1wt/flox::Cx3Cr1-Cre− (WT) microglia from male mice (named Het). (D) Selection of the most statistically significant Predicted Upstream Regulators obtained by Ingenuity Pathway Analysis of the DEGs comparison of Bin1flox/flox::Cx3Cr1-Cre+(Homo KO) versus Bin1wt/flox::Cx3Cr1-Cre− (WT) microglia from male mice (named Homo) and the DEGs comparison of Bin1wt/flox::Cx3Cr1-Cre+(Het KO) versus Bin1wt/flox::Cx3Cr1-Cre− (WT) microglia from male mice (named Het). (E,F) Plots representing mRNA expression (mean ± SD) of Cmp4b, Hspa8, Hsp90aa1, Hsp90ab1, Dnaja1 and Dnajb1 in WT and Bin1-cKO microglia from male mice, expressed as Fragments Per Kilobase Million (FPKM). Adjusted p-value: *padj < 0.05; **padj < 0.01; ***padj < 0.001; ****padj < 0.0001.
Figure 6 Deletion of Bin1 in microglia affects gene expression in a sexually dimorphic fashion. (A) Heatmap representing FPKM values of 268 differentially expressed genes in microglia from Bin1flox/flox::Cx3Cr1-Cre+, Bin1wt/flox::Cx3Cr1-Cre+ and Bin1wt/flox::Cx3Cr1-Cre− male and female mice (Average Normalized Counts > 4; Fold Change |FC| 1.5; padj < 0.05). (B) Venn diagram representing the distribution of 268 differentially expressed genes across genotypes and sexes. (C) Selection of the most statistically significant Canonical Pathways obtained by Ingenuity Pathway Analysis of the DEGs comparison of Bin1flox/flox::Cx3Cr1-Cre+(Homo KO) versus Bin1wt/flox::Cx3Cr1-Cre− (WT) microglia from male mice (named Homo) and the DEGs comparison of Bin1wt/flox::Cx3Cr1-Cre+(Het KO) versus Bin1wt/flox::Cx3Cr1-Cre− (WT) microglia from male mice (named Het). (D) Selection of the most statistically significant Predicted Upstream Regulators obtained by Ingenuity Pathway Analysis of the DEGs comparison of Bin1flox/flox::Cx3Cr1-Cre+(Homo KO) versus Bin1wt/flox::Cx3Cr1-Cre− (WT) microglia from male mice (named Homo) and the DEGs comparison of Bin1wt/flox::Cx3Cr1-Cre+(Het KO) versus Bin1wt/flox::Cx3Cr1-Cre− (WT) microglia from male mice (named Het). (E,F) Plots representing mRNA expression (mean ± SD) of Cmp4b, Hspa8, Hsp90aa1, Hsp90ab1, Dnaja1 and Dnajb1 in WT and Bin1-cKO microglia from male mice, expressed as Fragments Per Kilobase Million (FPKM). Adjusted p-value: *padj < 0.05; **padj < 0.01; ***padj < 0.001; ****padj < 0.0001.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 73 references

Cited by

See all 178

Metadata

Authors
Crotti, A., Sait, H. R., McAvoy, K. M., Estrada, K., Ergun, A., Szak, S., Marsh, G., Jandreski, L., Peterson, M., Reynolds, T. L., Dalkilic-Liddle, I., Cameron, A., Cahir-McFarland, E., & Ransohoff, R. M.
Affiliations
Biogen (United States) (US)
Corresponding author
Crotti, Andrea
Venue
Scientific Reports
Published
2019-07-01
Volume
9
Issue
1
Pages
9477-9477
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2954072698
Cited by
171
References
73
Citations by year
2026: 11 · 2025: 25 · 2024: 22 · 2023: 19 · 2022: 32 · 2021: 33 · 2020: 25 · 2019: 3
FWCI
15.79
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Biogen
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
BIN1, tau protein, extracellular vesicles, exosomes, Alzheimer's disease, late-onset Alzheimer's disease, microglia, tau seeding, cerebrospinal fluid, heat shock proteins, sex differences, PS19 mice
MeSH terms
Extracellular Vesicles, Proteostasis, Alzheimer Disease, Animals, Female, Gene Expression Regulation, Humans, Male, Mice, Transgenic, Nerve Tissue Proteins, Nuclear Proteins, Sex Characteristics, tau Proteins, Microglia, Tumor Suppressor Proteins, Adaptor Proteins, Signal Transducing, Mice, HEK293 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BIN1 favors the spreading of Tau via extracellular vesicles. https://app.cochat.ai/papers/10.1038/s41598-019-45676-0
The paper
Crotti, A., Sait, H. R., McAvoy, K. M., Estrada, K., Ergun, A., Szak, S., Marsh, G., Jandreski, L., Peterson, M., Reynolds, T. L., Dalkilic-Liddle, I., Cameron, A., Cahir-McFarland, E., & Ransohoff, R. M. (2019). BIN1 favors the spreading of Tau via extracellular vesicles. Scientific Reports. https://doi.org/10.1038/s41598-019-45676-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.